VJOncology is committed to improving our service to you

ASCO 2020 | Adjuvant treatment of colon cancer: three vs six months of FOLFOX/CAPOX

VJOncology is committed to improving our service to you

Alberto F. Sobrero

Alberto F. Sobrero, MD, Ospedale San Martino, Genova, Italy, discusses the final results from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration study. This study evaluated overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter